Gary Palmer

This resolution expresses recognition that the Air Force’s Strategic Basing Action process complied with law and policy and was justified in identifying Huntsville, Alabama, as the preferred permanent location for Space Command Headquarters.

This resolution recognizes Volkert, Inc., headquartered in Alabama, for its 100th anniversary and its contributions to engineering, infrastructure, and economic development.

This resolution prohibits the Office of the Chief Administrative Officer of the House of Representatives from accepting, distributing, or delivering Chinese Communist Party-controlled publications (e.g., China Daily).

**No Regulation Through Litigation Act of 2025** This bill specifies that a federal agency may not enter into a consent decree that exceeds the authority of the court that enters the order related to the decree. It also limits the inclusion of attorney fees or litigation costs in consent decrees or settlement agreements that result in a regulation or guidance document.

**Second Chance for Moms Act of 2025** This bill requires labeling of the drug mifepristone to include certain information about the hormone progesterone and establishes a related telephone hotline. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)

**CBO Show Your Work Act** This bill requires the Congressional Budget Office (CBO) to make available to Congress and the public each fiscal model, policy model, and data preparation routine that the CBO uses to estimate the costs and other fiscal, social, or economic effects of legislation. For each estimate of the costs and other fiscal effects of legislation, the CBO must also disclose, in a manner sufficient to permit replication by individuals not employed by the CBO, the data, programs, models, assumptions, and other details of the computations used to prepare the estimate. For data that may not be disclosed, the CBO must make available to Congress and the public * a complete list of all data variables for the data; * descriptive statistics for all data variables for the data, to the extent that the descriptive statistics do not violate the rule against disclosure; * a reference to the statute requiring that the data not be disclosed; and * contact information for the individual or entity who has unrestricted access to the data.

**No Abortion Coverage for Medicaid Act** This bill prohibits the Centers for Medicare & Medicaid Services from approving experimental, pilot, or demonstration projects under Medicaid (also known as Section 1115 Demonstrations) if the project provides federal financial assistance for abortions or for health benefits that include abortions, including expenses for related travel or lodging. The bill's restrictions do not apply to abortions in the cases of rape or incest; treatments to address life-threatening physical disorders, injuries, or illnesses; or treatments for miscarriages or ectopic pregnancies.

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.

This bill designates the facility of the United States Postal Service located at 401 North Elm Street in Tuskegee, Alabama, as the "Tuskegee Airmen Memorial Post Office".